Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.
Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis.
Improved detection of cortical MS lesions with phase-sensitive inversion recovery MRI.
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.
Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth.
Toxicity of Teriflunomide in Aryl Hydrocarbon Receptor Deficient Mice.
Ofatumumab Dose-finding in RRMS Patients
Macrophage-specific chemokines induced via innate immunity by amino acid copolymers and their role in EAE.
Regulation of prefrontal cortex myelination by the microbiota.
LETHAL MULTIPLE SCLEROSIS RELAPSE AFTER NATALIZUMAB WITHDRAWAL.
Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases.
Oligodendrocyte death results in immune-mediated CNS demyelination.
Change in the clinical development program for laquinimod
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
FTY720 in patients with primary progressive multiple sclerosis (INFORMS)
Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Trials
Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolomod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Immune status following alemtuzumab treatment in human CD52 transgenic mice.
Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.
Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.
TECFIDERA® Data Confirm Strong and Sustained Efficacy in Newly Diagnosed MS Patients and Real-World Effectiveness
[Evaluation and quantification of spasticity: a review of the clinical, biomechanical and neurophysiological methods].
Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis.

Pages